The recent controversy surrounding Replimune Group’s melanoma therapy has quickly become a proxy battle over the U.S. Food and Drug Administration itself. In the face of complex and sometimes conflicting clinical evidence, reasonable people can disagree about the merits of a particular therapy. But focusing on whether this one drug should be approved risks missing the more important issue. For innovators, the central question is not whether the FDA has strict standards. It is whether the agency applies its standards consistently.
In recent months, the agency has emphasized its commitment to faster approvals, greater flexibility in clinical trial design, and a more innovation-friendly posture. Those are welcome developments. But they sit uncomfortably alongside a growing perception among firms and investors that the rules of the game are becoming harder to read. Among the concerns are shifting evidentiary standards, less reliable guidance, and decisions that seem harder to anticipate even when firms believe they have followed the agency’s lead.
That disconnect matters. Drug development is an inherently risky enterprise, but it is a risk that can be priced, as long as the underlying rules are stable and transparent. When the mapping from evidence to regulatory decision becomes uncertain, the effect is not simply delay. It is a tax on innovation.
That tax shows up in important ways. The cost of capital rises. Investors demand higher returns to compensate for regulatory ambiguity. And companies do what businesses always do under uncertainty: they wait, scale back, or redirect money toward safer, later-stage, incremental products with clearer regulatory pathways. Smaller firms, which lack the resources to absorb long delays or conflicting messages from regulators, are disproportionately affected. Over time, the pipeline narrows.
One broader welfare point is often overlooked. Regulatory decisions are judged by the harms they prevent: unsafe or ineffective drugs that never reach patients. Those harms are visible and immediate. But the benefits of a more consistent and reliable regulatory process are easier to miss because they often show up as absences: the patient who remains on an inferior therapy for another year, the trial that never opens, the treatment that arrives too late. Medical progress slows not in one dramatic moment, but through a steady drip of delays and abandoned projects.
The consequences extend beyond the set of drugs that make it to market. Medical innovation generates spillovers that ripple through the broader economy and healthcare system. When a new therapy is introduced, it does more than treat patients. It changes how physicians practice, prompting new diagnostic approaches and new care pathways. It generates knowledge that informs future research, often across disease areas. It also supports a network of clinical trials, manufacturing capacity, and the investigators, trial sites, and scientific know-how that make the next breakthrough easier to develop.
These spillovers depend on a steady flow of innovation. When that flow is disrupted, the losses compound. Fewer trials mean less learning. The stakes are higher when firms begin to consider running early-stage trials outside the U.S., as some have recently suggested. When trials move, learning moves with them. So do experienced investigators, manufacturing know-how, and eventually the next generation of startups. Once that ecosystem shifts, it is difficult to rebuild.
This tension is especially consequential right now. The FDA does not need to become less rigorous to address this problem. But it does need to become a more consistent, reliable partner. Clearer guidance, more stable evidentiary expectations, and sufficient internal capacity to engage with developers early and often would go a long way toward aligning the agency’s actions with its stated goals.
Speed matters. But for an industry built on long timelines and large, irreversible investments, consistency matters more.
